We are currently making some changes to how orders are placed and because of this there will be a
short disruption period affecting order processing. Thank you for your patience while we work to
operate as smoothly as possible (November 14, 2023).
ESi006-A
SP13#4
iPSC line
Purchases have been temporarily disabled, as we are transitioning sales and distribution.
If you are interested in purchasing this cell line, please contact EBiSC directly. For more information about the current transition process see here.
If you are interested in purchasing this cell line, please contact EBiSC directly. For more information about the current transition process see here.
You will need to complete a Cell Line Information Pack (CLIP) before purchasing your cell line.
Please contact us to receive the relevant document.
The EBiSC Access and Use Agreement must be completed along with an individual
Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
for countersignature. The EAUA must be fully signed before proceeding with your order.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
hPSCreg Name | ESi006-A |
Alternative name(s) |
SP13#4
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
STBCi004-B-1 (SFC832-03-06 LRRK2WT/WT C47) Donor's gene variants: LRRK2 Donor diseases: Parkinson disease EDi001-A-2 (AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-3 (AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A (AST22, AST23, SAMEA3319992) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi008-B (G51D-4, EDINi008-B, EDIi008-B, SAMEA3174606) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease |
Provider |
|
Depositor | Spanish Stem Cell Bank (ES) |
Distributors |
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)
|
Derivation country | Spain |
External Databases |
|
hPSCreg | ESi006-A |
BioSamples | SAMEA3303225 |
Cellosaurus | CVCL_V203 |
CLO | CLO_0101547 |
Wikidata | Q54955440 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information#
General Donor Information |
|
Sex | female |
Age of donor (at collection) | 65-69 |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Disease associated phenotypes |
|
External Databases (Donor) |
|
BioSamples | SAMEA3303187 |
hIPSC Derivation#
General |
|
Source cell type |
keratinocyteAn epidermal cell which synthesizes keratin and undergoes a characteristic change as it moves upward from the basal layers of the epidermis to the cornified (horny) layer of the skin. Successive stages of differentiation of the keratinocytes forming the epidermal layers are basal cell, spinous or prickle cell, and the granular cell.
|
Age of donor (at collection) | 65-69 |
Reprogramming method |
|
Vector type | Integrating |
Vector | Virus (Retrovirus) |
Genes | |
Is the used vector excisable? |
Unknown |
Absence of reprogramming vector(s)? |
Unknown |
Reprogramming vectors silenced? |
Yes |
Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions#
Latest released batch |
|
Culture medium | mTeSR |
Passage method | EDTA |
Surface coating | Matrigel / Geltrex |
O2 concentration | 21 |
CO2 concentration | 5 |
Temperature | 37 |
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating | Gelatin | |||||||||||||||
Feeder cells |
Human foreskin fibroblasts Cellfinder Ont Id: CELDA_000001419 |
|||||||||||||||
Passage method | Mechanically | |||||||||||||||
CO2 Concentration | 5 % | |||||||||||||||
Medium |
Other medium:
Base medium: Knockout DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
Characterisation#
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
Alkaline Phosphatase |
Yes |
|
||||
NANOG |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
||||
SSEA-3 |
Yes |
|
||||
SSEA-4 |
Yes |
|
||||
TRA 1-60 |
Yes |
|
||||
TRA 1-81 |
Yes |
|
||||
SOX2 |
Yes |
|
Differentiation Potency
In vivo teratoma
In vitro spontaneous differentiation
Marker | Expressed |
SMA |
Yes |
In vivo teratoma
In vitro spontaneous differentiation
Marker | Expressed |
Tuj1 |
Yes |
GFAP |
Yes |
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Genotyping#
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Is there genome-wide genotyping or functional data available? |
Yes
|